Background and Objectives. Efforts to ensure that funded research represents ''value for money'' have led to increasing calls for the use of analytic methods in research prioritization. A number of analytic approaches have been proposed to assist research funding decisions, the most prominent of which are value of information (VOI) and prospective payback of research (PPoR). Despite the increasing interest in the topic, there are insufficient VOI and PPoR applications on the same case study to contrast their methods and compare their outcomes. We undertook VOI and PPoR analyses to determine the value of conducting 2 proposed research programs. The application served as a vehicle for identifying differences and similarities between the methods, provided insight into the assumptions and practical requirements of undertaking prospective analyses for research prioritization, and highlighted areas for future research. Methods. VOI and PPoR were applied to case studies representing proposals for clinical trials in advanced non-small-cell lung cancer and prostate cancer. Decision models were built to synthesize the evidence available prior to the funding decision. VOI (expected value of perfect and sample information) and PPoR (PATHS model) analyses were undertaken using the developed models. Results and Conclusions. VOI and PPoR results agreed in direction, suggesting that the proposed trials would be cost-effective investments. However, results differed in magnitude, largely due to the way each method conceptualizes the possible outcomes of further research and the implementation of research results in practice. Compared with VOI, PPoR is less complex but requires more assumptions. Although the approaches are not free from limitations, they can provide useful input for research funding decisions. Key words: research prioritization; value of information; prospective payback of research; expected value of sample information. (Med Decis Making 2016; 36: 321-334) T he advance of evidence-based decision making in health care has highlighted the need for rigorous information on the effectiveness and ''value for money'' of treatments and has led to an increasing demand for clinical evaluative research. At the same time, public research resources are limited, and hard choices are often needed on how the available budget should be allocated across competing research activities.
A number of analytic models have been developed and put forward to identify the value of conducting research and to assist with prioritization decisions. [1] [2] [3] [4] [5] On the basis of the principles underpinning them, 2 main analytic frameworks have been typically distinguished in the literature 6, 7 value of information (VOI) and prospective payback of research (PPoR). The approaches present similarities, but they differ in the way they conceptualize the value of research. 7, 8 VOI infers this value by looking at the expected benefits of making a decision in the light of improved information and reduced uncertainty, 9, 10 while PPoR calculates the benefits that research may bring about by triggering a beneficial change in clinical practice. 2, 3, 7 While prospective analytic assessments are not currently part of the research prioritization process, there have been increasing calls for their use and a growing interest in exploring their potential role. 4, [11] [12] [13] [14] At the same time, there is a steady stream of academic research aiming to address methodological issues in analytic methods, particularly in VOI. 15, 16 Nonetheless, practical applications of PPoR and VOI on the same case study for the purpose of contrasting and comparing the approaches are scarce. The only study available in the literature 17 gives useful insights, but it reports only basic VOI calculations, which are unlikely to represent the full potential of the approach 18 or reveal the true level of complexity in its calculations. 19, 20 With this in mind, we set out to apply PPoR and VOI analyses to 2 case studies representing proposals for clinical trials. The application aimed to give prospective estimates of the expected value of undertaking the proposed trials as calculated by each of the methods. As well as adding to the existing literature of practical applications, this work provided a vehicle for exploring the similarities and differences between the frameworks, provided insight into the practical requirements and use of assumptions associated with these analyses, and suggested areas for further research.
METHODS
VOI and PPoR were applied to 2 stylized case studies representing proposals for clinical trials in non-small-cell lung cancer (NSCLC) and advanced castrate-refractory prostate cancer (CRPC). The methods were applied retrospectively, to identify the expected benefits of the proposed trials at the point when funding was considered. The analyses were carried out in 2 stages. In the first, preliminary, stage, information existing up to the point when the research proposals were submitted for funding was synthesized through purpose-built decision models. In the second stage of the analyses, the developed models served as a basis for applying PPoR and VOI to determine the value of conducting the proposed trials. In this work, case studies aimed to serve as a platform for obtaining insights into the use of PPoR and VOI rather than to inform actual treatment recommendations or research funding decisions.
Case Study 1: Trial in Non-Small-Cell Lung Cancer
The standard of care for advanced NSCLC patients aims to prolong life or palliate symptoms and comprises a combination of a platinum analog with third-generation chemotherapy, in which gemcitabine is often used as the parent drug. [21] [22] [23] Two platinum agents have been traditionally used, cisplatin and carboplatin; however, the choice between them has been contentious, owing to uncertainty around their effectiveness, toxicity, and cost-effectiveness. 24 In view of this, a trial was proposed in 2004 to compare gemcitabine plus cisplatin (Gem+Cisp) and gemcitabine plus carboplatin (Gem+Carb) in patients with advanced (stage IIIB/IV) NSCLC. The proposal was submitted to Cancer Research UK and requested a grant of £336,700.
Case Study 2: Trial in Castrate-Refractory Prostate Cancer
Advanced CRPC typically spreads to bones, which in turn results in severe skeletal pain. A number of agents have been developed for palliating the morbidity from bone metastases, including chemotherapy, 25 radioisotopes, 26 and bisphosphonates. 27, 28 In the UK, these treatments are usually used singly in sequence. Two agents that have been proven beneficial in skeletal-related problems are zoledronic acid (ZA) and strontium-89 (Sr89). 29 An early-stage trial, the Taxane Radioisotope Zoledronic Acid (TRAPEZE) phase II trial, investigating these treatments in combination with standard chemotherapy was successful in securing funding, and continuation of this study to a phase III randomized controlled trial involving a larger sample was proposed in 2006. The proposal was submitted for funding to the National Institute for Health Research (NIHR) Health Technology Assessment program and requested a grant of £2.54 million.
Decision Modeling and Cost-effectiveness Analysis
A decision model was developed for each case study. In the case of NSCLC, the model comprised 3 states: progression-free (PG-F), progression (PG), and death (D). Patients in the PG-F state receive either Gem+Cisp or Gem+Carb and stay in this state until death or disease progression. Upon progression, patients move to PG and, eventually, to the death state D.
The CRPC model assessed the cost-effectiveness of 4 chemotherapy options: 1) docetaxel and prednisolone (DP); 2) DP with zoledronic acid (DP+ZA); 3) DP with strontium-89 (DP+Sr89); and 4) DP with zoledronic acid and strontium-89 (DP+ZA+Sr89). The model consisted of 4 health states: progressionfree, on treatment (PGF-OT); progression-free, not on treatment (PGF); progression (PG); and death (D). CRPC patients with stable disease enter the model in the PGF-OT state, where they receive 6 cycles of chemotherapy, with each cycle lasting 3 weeks. Patients stay in this state for 6 cycles, unless they die or discontinue treatment. At the end of the treatment course, patients who have completed all 6 cycles move to the PGF state. Upon progression, patients move to the state PG and, eventually, to state D. Details on the structure of each model are given in Appendix A (available online).
Analyses were carried out from the perspective of the National Health Service in the UK. Inputs for the models were obtained from the literature available at the time each of the decisions was considered. In the CRPC model, key information on progression rates was available from phase II of the TRAPEZE trial. To account for uncertainty, key model parameters were represented as probability distributions 8 (Appendix A). Because parameters were obtained from various sources, the correlation structure between them is usually not known, so the analysis effectively assumes that parameters are independent. Since this may not be the case, results need to be interpreted with caution. Monte Carlo methods were used to obtain 5000 simulated estimates of incremental costs and quality-adjusted life-years (QALYs), 30 which were subsequently converted into net monetary benefits (NMBs). 31 The latter measure translates health gains into monetary terms using as an exchange rate a hypothetical value of the decision maker's (or society's) willingness to pay for a unit of benefit. A conventional willingness to pay value of £30,000 per QALY was used throughout; other values are equally applicable.
Value of Information
Value of information analysis is part of statistical decision theory-a collection of analytic techniques aimed to assist decision making under conditions of uncertainty. 32, 33 The framework builds on the premise that choices between different options made under uncertainty about their true payoffs may turn out to be erroneous. Thus, uncertainty imposes an expected loss of benefits, which can be minimized if more information on the true payoffs becomes available. Measures of VOI seek to quantify the expected opportunity loss from decision making under uncertainty, with a view to inferring the value of obtaining additional information through research. Given this, VOI has been often advocated as a formal analytic framework to assist with topic prioritization for clinical evaluative research 34, 35 as well as to guide funding decisions and determine efficient research design. 19, 36, 37 A first metric often calculated in VOI analysis is the expected value of perfect information (EVPI). 15, 38 The EVPI for an individual patient is the difference between the expected benefits of making a decision with perfect and current information and can be calculated from the simulated results of a probabilistic model as
where j represents the alternative options of interest, and u represents all the uncertain parameters affecting the decisions. 20 Under current information, without knowing the true values of the uncertain parameters u, the optimal decision is made by averaging over the NMBs associated with all possible values of u and selecting the intervention with the greatest expected (average) net benefits (max j E u NMB (j,u)). If perfect information was available, the decision maker would know which value u would take and would choose the intervention with the maximum NMBs for that particular value of u. As the true value of u is not known in advance, determining the expected net benefits from a decision under perfect information requires first obtaining the maximum NMBs for every possible value of u and taking the mean across all the obtained maximum NMBs (E u max j NMB (j,u)). EVPI can be thought of as the maximum returns to conducting research around a decision problem and may be used as a first hurdle in recommending further research: If the cost of a further study exceeds the maximum benefits expected from this study (i.e., the EVPI), conducting further research should be ruled out. 4 A more informative measure for research prioritization is the expected value of sample information (EVSI). EVSI shows the expected benefit of making a recommendation in light of improved information drawn from research such as a clinical trial of a given sample size. EVSI represents the difference between the benefit expected from a decision with sample information and the benefit expected from the same decision made under current information. Owing to the complexity of EVSI calculations, the method is typically restricted to assessing the value of a clinical trial in informing one or a group of similar parameters. 8 Here, parameters of interest were the probabilities of disease progression and death for each case study. Assuming that a trial of sample size n is considered to provide evidence on the parameters of interest u of all uncertain parameters u, per-patient EVSI can be calculated as
This formula is analogous to the formula for EVPI, but the expected net benefit after the proposed trial is dependent on the trial result, which is represented by a summary statistic D.
The process of calculating the expected benefit of a decision made under sample information requires simulating the possible results of a trial, taking into account any prior (i.e., existing) information, and combining this prior information and possible results into posterior information using Bayesian methods. The posterior information is, in turn, translated into a distribution of the expected NMB through the decision models. Subtracting the cost of research from the EVSI gives the expected net benefit of sampling (ENBS), a measure of the net value of the trial. 20, 39 The ENBS is seen as the net payoff to a proposed study, and it represents the sufficient condition for conducting this study: If ENBS is positive, further experimental research will be beneficial. 39 Detailed explanations of EVPI and EVSI calculations are provided by Ades and others 20 and Briggs and others. 8 The steps involved in calculating EVSI and ENBS can be seen in Appendix B (available online).
The EVPI (and similarly EVSI) values for the whole population of eligible patients can be calculated as
Here, d is the time lag between a funding decision and dissemination of results, measured in relevant time periods, I t represents the population of eligible patients at time t, and r is the discount rate applied to account for positive time preference. In this study, the discount rate used is 3.5% per year and the time horizon T is set at 5 years for the NSCLC case study and 2 years for the CRPC study based on expert opinion. Given a yearly incidence of 3830 and 3330 chemotherapyeligible NSCLC and CRPC patients, 40 ,41 the total undiscounted number of patients who stand to benefit from research was estimated at 19,150 and 6660 for NSCLC and CRPC, respectively. Assuming a time lag of 7 years from trial start to result dissemination, discounting at 3.5% per year effectively reduces these numbers to approximately 13,800 and 5100, respectively.
Prospective Payback of Research
PPoR is based on the concept that evidence generated through clinical evaluative research is valuable because it triggers changes in clinical practice; that is, the use of cost-effective treatments expands, and non-cost-effective treatments are contained or discontinued. 3, 5 Benefits accruing due to such changes in clinical practice are seen as a proxy for the value of the proposed research and can be calculated as the difference between 2 states of the world: 1) a factual state in which research takes place and triggers changes in clinical practice, and 2) a counterfactual state, in which research is not conducted and clinical practice remains largely as it is. 2, 3, 42 A number of models following the principles of the PPoR framework have been put forward over the last 30 years 2, 3, 11, 42, 43 ; this study follows the methods in the most recent of them, the Preliminary Assessment of Technologies for Health Services (PATHS) model. 11 To estimate the population costs and benefits expected to accrue in the factual and counterfactual states, information is needed about 1) the per-patient costs and effectiveness of the treatments provided to patients, and 2) the use of these treatments in clinical practice, in terms of the proportion of patients receiving each treatment. In a prospective framework, the per-patient costs and benefits associated with each treatment are unknown (although some prior evidence may exist) and are expected to be revealed by research. As results cannot be known in advance, the approach specifies a series of scenarios. These scenarios, taken one at a time, reflect the true underlying effectiveness and cost-effectiveness of the compared treatments, which are assumed to hold true irrespective of whether research does take place and reveals them. Each scenario is associated with a particular research outcome and is expected to have an impact on clinical practice.
Three broad outcomes are usually hypothesized and specified in PPoR studies 11, 17 : 1) a favorable outcome, under which research results for a treatment of interest are hypothesized to be such that when these are translated into cost-effectiveness estimates, the treatment appears cost-effective; 2) an inconclusive outcome, under which results show the treatment to be of inconclusive cost-effectiveness; and 3) an unfavorable outcome, under which the hypothesized research results are such that the treatment is not cost-effective. To match the favorable, inconclusive, and unfavorable outcomes above, hypothetical research results are typically specified in terms of key estimates of the treatments' effectiveness. In this study, estimates of the effectiveness were the probability of disease progression at 12-month follow-up for NSCLC and the probability of transition from progression-free to progression states for CRPC.
If research was conducted, observing each of these hypothetical outcomes would be expected to induce a change in treatments' prescription shares. Possible prescription patterns following the specified outcomes were determined after discussion with experts in cancer services commissioning. In both case studies it was assumed that in the absence of research, prescription shares will largely remain at current levels. Specified scenarios and hypothesized results and change in clinical practice for the NSCLC and CRPC case studies are given in Appendix C. Given the possible outcomes and the hypothesized change in clinical practice, a measure of the additional benefit of research is estimated as
Here, i is an indicator for the possible outcome, r and nr index the ''with research'' and ''without research'' situations, C st represents the cost of the proposed research study, and C r,i and C nr,i are the costs associated with outcome i in the ''with research'' and ''without research'' situations, respectively. Last, E r,i and E nr,i are the effects (e.g., QALYs) associated with research and without research, respectively, under outcome i, and l stands for a decision maker's willingness to pay for a unit of effect. The above formula gives the benefit expected to accrue from each possible outcome, but only 1 of these outcomes will come true. Although it is not known in advance which of the outcomes will transpire, summary measures of the proposed study's payoff can be obtained by creating combinations where each possible outcome is weighted by a predetermined likelihood of occurrence. 11 Three combinations have been typically formed in the literature 11, 17 : 1) an optimistic combination, where the probability of observing a positive, inconclusive, and negative outcome is 0.5, 0.25, and 0.25, respectively; 2) a neutral combination, where each outcome has a one-third probability of being observed; and 3) a pessimistic combination, where the probability of observing a positive, inconclusive, and negative outcome is 0.25, 0.25, and 0.5, respectively. Following the previous notation, the weighted incremental NMB for a combination is given by
where k is an index for combinations and p i is the probability of observing study outcome i. Similarly to the VOI analysis above, patient NMB in PPoR is extrapolated to the eligible population over a specified time horizon (5 and 2 years for NSCLC and CRPC, respectively), starting after research results are expected to be disseminated (7 years).
RESULTS OF CASE STUDY 1: TRIAL IN NSCLC

Cost-effectiveness Results for the NSCLC Case Study
In light of evidence existing up to the point of the trial funding decision, results of the NSCLC model suggested that Gem+Cisp is less costly and more effective than Gem+Carb, resulting in mean cost savings of approximately £740 and a mean gain of 0.015 QALYs per patient. At a willingness to pay value of £30,000 per QALY, the results translate into £11,660 and £10,472 NMBs for Gem+Cisp and Gem+ Carb, respectively. At the particular threshold, the probability of Gem+Cisp being more cost-effective than Gem+Carb is approximately 0.64.
VOI Analysis Results for the NSCLC Case Study
The EVPI for the decision between Gem+Carb and Gem+Cisp was calculated at £950 and £13.08 million for the individual and the population, respectively. The results suggest that at £30,000 per QALY, conducting research to provide further evidence around the NSCLC treatment adoption decision would be potentially-although not necessarilyworthwhile if the research program costs less than £13.08 million. On this basis, funding and carrying out the proposed research, which required a grant of £336,700, would be a potentially worthwhile investment.
For the sample of 450 patients per treatment arm specified in the trial proposal, the EVSI was calculated at £677 for the individual patient and £9.33 million for the likely population of eligible patients over 5 years. Comparing EVSI with the cost of the trial gives the ENBS, an estimate of the net value of the trial. 39 Given the cost of £336,700 for the proposed trial, the expected net benefit of the trial is £9 million. A graph of EVPI and EVSI at different willingness to pay values is given in Figure 1 .
PPoR Analysis Results for the NSCLC Case Study
PPoR results for each specified outcome are presented in Table 1 . Under the favorable outcome for Gem+Carb, carrying out research is estimated to result in higher costs and more QALYs compared with a situation without research. Given that each additional QALY in this case would require an investment of less than £30,000, conducting research would result in a positive NMB of about £2.22 million. Under the inconclusive outcome, conducting research is associated with no additional QALYs (as no change in uptake is expected to take place) for an extra cost due to conducting the trial. In this case, there will be a cost of about £336,700 for no additional benefits and a negative NMB of -£336,700. Under the unfavorable outcome for Gem+Carb, conducting research is associated with an increase in QALYs and cost savings, due to limiting the use of the more costly and less effective Gem+Carb in the population. In this situation, carrying out research appears particularly appealing, as it is predicted to result in an NMB of £3.82 million.
Possible outcomes were assigned weights representing the likelihood of observing each outcome. Three different probability distributions of outcomes were compared ( Table 2 ). In line with the PATHS method, such combinations aim to reflect the likelihood of observing the determined outcome rather than the probability of obtaining definitive results that would resolve this decision problem. Assuming a willingness to pay value of £30,000 per additional QALY, carrying out research would be a worthwhile investment, estimated to result in positive NMBs of £1.98 million, £1.88 million, and £2.38 million under the optimistic, neutral, and pessimistic combinations, respectively. £0 £10,000,000 £20,000,000 £30,000,000 £40,000,000 £50,000,000 £0
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populaƟon EVPI populaƟon EVSI (n=450) Figure 1 Population expected value of perfect information (EVPI) and expected value of sample information (EVSI) for non-small-cell lung cancer (NSCLC) case study.
RESULTS OF CASE STUDY 2: TRIAL IN CRPC
Cost-effectiveness Results for the CRPC Case Study
In relation to CRPC treatments, the cost-effectiveness analysis showed that 2 options (DP+ZA and DP+ ZA+Sr89) were dominated. Of the remaining 2 options, DP+Sr89 was associated with a greater cost, more QALYs, and an incremental cost-effectiveness ratio (ICER) of about £8100 per additional QALY compared with DP (the other nondominated treatment). Probabilistic results showed DP+Sr89 to have the highest probability of being cost-effective, just over 0.53.
VOI Analysis Results for the CRPC Case Study
The per-patient EVPI for the decision related to CRPC was estimated at £1680, and the equivalent value for the population of eligible patients over a 2-year time horizon was £8.55 million. On the basis of this estimate, and given a cost of £2.54 million for the proposed phase III trial, conducting the trial to provide evidence around the CRPC treatment adoption decision would be potentially worthwhile. Given a willingness to pay of £30,000 per QALY, the EVSI for 300 patients per arm was estimated at £605 and £3.09 million for the individual and the population, respectively. At a cost of £2.54 million, this trial would result in ENBS of about £550,000, suggesting that the trial is a worthwhile investment. The obtained EVPI and EVSI curves at different values of willingness to pay for a QALY can be seen in Figure 2 .
PPoR Analysis Results for the CRPC Case Study
PPoR results for each of the specified research outcomes are given in Table 3 . Under an outcome favorable for DP+Sr89, there would be costs due to conducting the trial and moving from DP toward the more costly DP+Sr89, but there would also be gains in QALYs, resulting in overall NMB gains of £5.13 million. Under the ''inconclusive'' scenario, there would be a loss of £2.54 million due to the expenditure for the ''inconclusive'' trial. Under any outcome unfavorable for DP+Sr89, there would be cost savings from restricting the use of more expensive nonstandard treatments, and additional QALYs, resulting in positive NMB ranging from £307,200 to £5.07 million.
Each outcome was assigned a weight representing its probability, to form combinations. In each of a series of alternative combinations, a weight of 0.5 was given to observing favorable results for a specific treatment, with the likelihood weight for the rest of the results being 0.125. The analysis showed that funding and conducting the proposed phase III trial would be beneficial, and it is expected to lead to a NMB between £1.54 and £3.34 million (Table 4 ).
COMPARISON OF PPOR AND VOI
The applications revealed a number of similarities between VOI and PPoR. Essentially, both frameworks build on the idea that the value of research can be inferred from the additional benefits brought about by the availability of improved information. To estimate these benefits, both PPoR and VOI specify possible results of research and assess the returns from research using measures and techniques commonly seen in economic evaluation of health care technologies. In both frameworks, the value of research relates to quantifiable benefits in the population, while none of the approaches aims to capture any wider economic and educational benefits from engaging in research.
Despite these similarities, there are notable differences in the rationales underpinning PPoR and VOI. To a large extent, VOI results depend on the degree of the existing uncertainty around the true payoffs of competing options (e.g., treatments) and the associated expected loss of benefits due to this uncertainty. On this basis, further research appears more desirable when uncertainty around the optimal treatment is high, the expected loss of benefits due to uncertainty is substantial, and the cost of further research is Figure 2 Population expected value of perfect information (EVPI) and expected value of sample information (EVSI) for castrate-refractory prostate cancer (CRPC) case study.
relatively low. In contrast, PPoR results are driven by the hypothesized magnitude of change in clinical practice following research rather than by the degree of uncertainty around the optimal treatment. Given this, PPoR estimates are expected to be favorable for research proposals on treatments that are used commonly in clinical practice but for which further research may trigger a substantial change in their use. The fact that PPoR places prime importance on change in clinical practice has been criticized on the grounds that the approach sees research as a way of changing clinical practice rather than as a means of reducing uncertainty. 7, 34 The results of the case studies showed that estimates produced by PPoR and EVSI agreed in direction, suggesting that the proposed trials in NSCLC and CRPC would be cost-effective investments. However, results differed in magnitude, owing to differences in the methods and calculations used by each approach. In EVSI, possible research outcomes are obtained through formal Bayesian methods that combine existing information with simulated data. In contrast, possible outcomes in PPoR are typically specified on the basis of expert opinion 11 or researchers' assumptions, 17 bearing in mind that these should represent plausible results, cover different eventualities, and have an impact on clinical practice. While specification of possible outcomes in PPoR is relatively straightforward, the use of essentially arbitrary values adds a layer of subjectivity to the analysis. In general, a different conclusion would be drawn if the most likely outcome to occur were an inconclusive outcome, as this would result in costs due to undertaking the trial but no change in clinical practice and thus no additional benefit.
Further, the approaches differ in the way they account for implementation of research results in clinical practice. VOI results are typically calculated on the premise that any decision informed by further research would be implemented perfectly, so that all, rather than a proportion, of the eligible patients would benefit from the availability of further evidence. As expected, the assumption of perfect implementation makes research appear more valuable and is reflected in the higher EVSI results. Recent work has suggested ways of relaxing this assumption in the context of EVSI, 44 but no applications of these calculations on EVSI values derived using nonparametric methods are available to date. In PPoR, assumptions around the implementation of research results are explicitly reflected in the hypothesized estimates of change in clinical practice and have a sizeable impact on the final results. In general, larger increases in the prescription shares of cost-effective treatments result in greater benefit. Indicatively, sensitivity analysis showed that the NSCLC and CRPC trials would be associated with negative NMB-thus, they would not be worth undertaking-if the use of Note: DP = docetaxel and prednisolone; NMB = net monetary benefit; NSCLC = non-small-cell lung cancer; PPoR = prospective payback of research; QALY = quality-adjusted life-year; Sr89 = strontium-89; ZA = zoledronic acid. a. Treatment option associated with the greatest NMB (at £30,000 willingness to pay per QALY) compared with the rest of the treatment. treatments shown to be cost-effective increased by less than 3.8 percentage points in NSCLC (i.e., from 50% to 53.8%, rather than to 75% assumed in the base case) and less than 18.5 percentage points in CRPC (i.e., from 5% to 23.5% for each of the treatments currently not in wide use, rather than to more than 40% assumed in base case). The extent to which such changes in prescription shares are likely to be achieved will depend on different factors, including the effectiveness of result dissemination strategies and the existence of appropriate infrastructure to support the change. 5 In the particular case studies considering the use of pharmaceuticals, it is thought that a change in implementation is unlikely to be hindered by significant barriers. While no estimates of the likely change in clinical practice are typically used in VOI, results are greatly affected by assumptions used in the decision analytic model, especially when these assumptions relate to the degree of uncertainty around key parameters. Typically, greater uncertainty in parameters is associated with greater values of EVSI. In addition, it must be noted that the degree to which VOI results are unbiased depends largely on the validity of the decision model through which results are produced. Flaws in the model-for example, incorrect structure and inappropriate representation of the joint distribution of uncertain parameters-may lead to inaccurate cost-effectiveness results and, consequently, biased estimates of EVSI. Finally, it is currently not evident how other pertinent considerations, such as the fact that treatments of interest may become available as less costly generic products in the future, can be accounted for within the VOI and PPoR frameworks.
Evidently, both PPoR and VOI are sensitive to assumptions about the used time horizon over which the produced evidence is expected to be useful. Long time horizons inflate the number of patients expected to benefit from the availability of improved information, increase the expected benefits in the population predicted by VOI and PPoR, and make further research appear more desirable. In contrast, shorter time horizons reduce the estimated benefits of conducting the studies: At current annual incidence rates, sensitivity analysis on PPoR results showed that the proposed trials would not result in additional benefits if trial results were useful for less than 9 months for NSCLC and less than 1 year for CRPC. In VOI, the trials would not be worth conducting if the time horizon was less than 2 months for NSCLC and less than 20 months for CRPC. Such short time horizons are not unusual in situations where pharmaceuticals may be expected to be superseded by newer treatments. It is worth noting that the use of assumptions in processes evaluating the costs and effects of different activities is, to a large extent, inevitable, be it health care programs or projects of public infrastructure. 45, 46 This would be expected to hold true for assessments of the value of future research, especially because such research is yet to take place and estimating its benefits requires guesses and predictions.
Methodological challenges also arise when PPoR is applied to case studies involving multiple comparisons, such as the CRPC study. The correct approach for dealing with such applications is unclear, while, at the same time, this task requires stronger assumptions when specifying possible outcomes. For instance, under the ''inconclusive'' scenario, all 4 treatments are assumed to be of similar cost-effectiveness, which is an unlikely situation. In comparisons between multiple treatments, different possible outcomes need to be specified in a way that covers all the possible eventualities. As a result, the number of PPoR results increases, which poses additional difficulties for decision makers in selecting the results that are more likely to transpire.
An important consideration for potential users of these methods is the time and expertise required for undertaking VOI and PPoR. 4, 11 This application showed that preliminary tasks-literature reviews to identify the existing information and decision modeling-were the most time-consuming elements of the analyses, taking approximately 6 months for each model. Once the decision models were constructed and their results became available, PPoR was carried out within 2 weeks of a researcher's full-time equivalent, while VOI took about 6 weeks, mostly due to time required for setting up the programming codes for EVSI calculations and running computations. While there was no difference in the computation needed for undertaking PPoR for the 2choice NSCLC and 4-choice PPoR decision problems, considerably more computation was needed for undertaking EVSI for CRPC than for NSCLC, due to the complexity of the CRPC model and the greater number of choices involved. Both VOI and PPoR were undertaken using a widely available spreadsheet application.
Previous work has looked into the time frames within which VOI (EVPI for all or a subset of uncertain parameters) and PPoR (PATHS model) analysis can be carried out. Claxton and colleagues 4 found that modeling and VOI would take a team of researchers approximately 10-12 weeks to carry out, while Townsend and others 11 suggested that PATHS analysis can be undertaken within 1-4 weeks, depending on the complexity of the project. These estimates are in broad agreement with observations from the present study. Evidently, if a systematic review and a decision model are already available for use, the analysis time required would be considerably shorter. It must be noted that in a situation where research results are expressed as final outcomes (e.g., QALYs) that can be readily combined with costs to inform decisions, PPoR and VOI may be conducted with minimal or no modeling. 11, 47 In addition, there has been ongoing research on identifying situations where complex EVSI calculations can be substituted by simpler methods, as well as advances in identifying shortcuts and efficient computation methods for estimating EVPI and EVSI. 20, [48] [49] [50] 
DISCUSSION
While PPoR and VOI have been often advocated for use in priority setting, 2,3,9 practical applications on the same case studies for the purpose of contrasting and comparing the approaches are scarce. Only 1 such application was found in the literature: Fleurence 17 applied VOI and PPoR to case studies of proposed clinical trials in the areas of osteoporosis and pressure ulcers. Both VOI and PPoR showed that further research would lead to additional benefits and suggested that the proposed trials in these areas would be cost-effective. The study by Fleurence 17 offers useful insights into the strengths and limitations of PPoR and VOI; however, its scope and conclusions are constrained by the fact that VOI analysis comprised only EVPI calculations. By undertaking EVSI analysis, one can obtain a more complete view of the value and potential of VOI and gain a more accurate picture of the complexity, computational requirements, and feasibility of undertaking such analyses.
Importantly, EVPI and PPoR calculations have different purposes and aim to answer different questions. EVPI gives the maximum expected benefits from further research, and, as such, it can only be used as a criterion for ruling out research that would not be worthwhile. EVPI results can be valuable in commissioned funding streams, which aim to identify and prioritize topics on which to commission further research. 4 In contrast, PPoR aims to calculate the expected benefits from specific trials, and thus its aims resemble more closely those of EVSI. Given this, EVSI and PPoR are better placed to help with funding decisions around specific trials and can be useful in researcher-led programs, where decisions are needed on whether proposals submitted by researchers on topics of their choice should be funded.
The present study sought to extend the existing literature by undertaking a practical application of PPoR (PATHS model) and VOI, with the latter including both EVPI and EVSI analyses. Strengths of this study include the use of a decision model developed to facilitate the PPoR and VOI applications. EVPI and EVSI were calculated according to well-established nonparametric methods. 8, 20 The PPoR analysis was based on the most contemporary and comprehensive version available in the literature 11 ; however, it must be noted that other PPoR versions 2,5 may have produced different results. A number of assumptions were required in this analysis; these are inherent to the assessed frameworks and aim to compensate for the lack of data. For example, empirical evidence on the time horizon over which information is expected to be useful, the likelihood of obtaining specific research results, and the future uptake of treatments in light of different research outcomes is typically unobserved, thus, estimates for these factors were, necessarily, obtained from expert opinion.
The practical application highlighted methodological limitations in both PPoR and VOI. With regard to PPoR, the framework would benefit from more explicit and systematic ways of determining possible research outcomes, given the fact that such outcomes affect the final results. Additional research would also be needed to look into appropriate ways of obtaining estimates of the likely uptake of treatments in clinical practice and the likelihood of a proposed trial showing the specified results. For the former, this may involve formal methods of eliciting expert opinion from adequately large groups of researchers, commissioners, and decision makers. For the latter, there may be scope for obtaining likelihood weights by combining expert opinion with existing evidence (e.g., existing results of other studies, phase II data), possibly by using Bayesian processes. 51, 52 In relation to VOI, there is a need for further developments in the method to ensure that results are appropriately adjusted for the loss of benefits due to imperfect implementation. Both methods would benefit from methodological work around appropriate ways of predicting the length of time over which information will be useful and establishing the relationship between availability of information and change in clinical practice.
Interestingly, ways of addressing the limitations of each approach may be identified by looking at their counterparts. EVSI may benefit from accounting for imperfect implementation in a way similar to that in PPoR, while PPoR would benefit from specification of possible research results in a way that combines prior and possible new evidence in an analytic way. Existing limitations do not appear to be more substantial-or less likely to be resolved by research-than methodological limitations and debates seen in economic evaluations of health care technologies. While the approaches are not a panacea, it is thought that they can provide useful input for research funding decisions and offer greater assurance that research resources are spent prudently.
